The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL1036     4-(4-chlorophenyl)-1-[4-(4- fluorophenyl)-4...

Synonyms: AGN-PC-00S4RN, AG-F-15706, SureCN4540106, CHEBI:223804, AC1L3OHZ, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Reduced haloperidol


Psychiatry related information on Reduced haloperidol


High impact information on Reduced haloperidol


Biological context of Reduced haloperidol


Anatomical context of Reduced haloperidol


Associations of Reduced haloperidol with other chemical compounds


Gene context of Reduced haloperidol


Analytical, diagnostic and therapeutic context of Reduced haloperidol


  1. Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. Chartoff, E.H., Ward, R.P., Dorsa, D.M. J. Pharmacol. Exp. Ther. (1999) [Pubmed]
  2. The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Brent, P.J., Pang, G., Little, G., Dosen, P.J., Van Helden, D.F. Biochem. Biophys. Res. Commun. (1996) [Pubmed]
  3. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Mihara, K., Suzuki, A., Kondo, T., Yasui, N., Furukori, H., Nagashima, U., Ono, S., Kaneko, S., Otani, K., Inoue, Y. Therapeutic drug monitoring. (2000) [Pubmed]
  4. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum. Allen, R.M., Lane, J.D., Brauchi, J.T. Eur. J. Pharmacol. (1980) [Pubmed]
  5. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. Yasui, N., Kondo, T., Otani, K., Furukori, H., Mihara, K., Suzuki, A., Kaneko, S., Inoue, Y. Journal of clinical psychopharmacology. (1999) [Pubmed]
  6. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia. Stevens, A., Mahal, A., Gaertner, H.J. Pharmacopsychiatry (1992) [Pubmed]
  7. Optimization of the separation of some psychotropic drugs and their respective metabolites by liquid chromatography. Cutroneo, P., Beljean, M., Luu, R.P., Siouffi, A.M. Journal of pharmaceutical and biomedical analysis. (2006) [Pubmed]
  8. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Mihara, K., Suzuki, A., Kondo, T., Yasui, N., Furukori, H., Nagashima, U., Otani, K., Kaneko, S., Inoue, Y. Clin. Pharmacol. Ther. (1999) [Pubmed]
  9. Reduced haloperidol and haloperidol: effects on homovanillic acid in caudate and prefrontal cortex. Chang, W.H., Wu, H.S., Tseng, Y.T. Biol. Psychiatry (1987) [Pubmed]
  10. Pharmacokinetics of haloperidol: an update. Kudo, S., Ishizaki, T. Clinical pharmacokinetics. (1999) [Pubmed]
  11. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pan, L.P., De Vriendt, C., Belpaire, F.M. Pharmacogenetics (1998) [Pubmed]
  12. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Suzuki, A., Otani, K., Mihara, K., Yasui, N., Kaneko, S., Inoue, Y., Hayashi, K. Pharmacogenetics (1997) [Pubmed]
  13. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Chang, W.H., Lam, Y.W., Jann, M.W., Chen, H. Psychopharmacology (Berl.) (1992) [Pubmed]
  14. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Jann, M.W., Lam, Y.W., Chang, W.H. Psychopharmacology (Berl.) (1990) [Pubmed]
  15. Neuroleptic-induced emotional defecation: effects of scopolamine and haloperidol. Sanberg, P.R., Russell, K.H., Hagenmeyer-Houser, S.H., Giordano, M., Zubrycki, E.M., Garver, D.L. Psychopharmacology (Berl.) (1989) [Pubmed]
  16. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Brent, P.J., Pang, G.T. Eur. J. Pharmacol. (1995) [Pubmed]
  17. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. Ko, G.N., Korpi, E.R., Kirch, D.G. Journal of clinical psychopharmacology. (1989) [Pubmed]
  18. Electrophysiological interactions between haloperidol and reduced haloperidol, and dopamine, norepinephrine and phencyclidine in rat brain. Kirch, D.G., Palmer, M.R., Egan, M., Freedman, R. Neuropharmacology (1985) [Pubmed]
  19. Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Korpi, E.R., Costakos, D.T., Wyatt, R.J. Biochem. Pharmacol. (1985) [Pubmed]
  20. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. Dysken, M.W., Kim, S.W., Vatassery, G., Johnson, S.B., Skare, S., Holden, L., Thomsyck, L. Journal of clinical psychopharmacology. (1992) [Pubmed]
  21. Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction. Someya, T., Shibasaki, M., Noguchi, T., Takahashi, S., Inaba, T. Journal of clinical psychopharmacology. (1992) [Pubmed]
  22. Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices. Monnet, F.P., de Costa, B.R., Bowen, W.D. Br. J. Pharmacol. (1996) [Pubmed]
  23. Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. Yasui-Furukori, N., Kondo, T., Mihara, K., Suzuki, A., Inoue, Y., De Vries, R., Kaneko, S. Journal of clinical pharmacology. (2002) [Pubmed]
  24. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Tyndale, R.F., Kalow, W., Inaba, T. British journal of clinical pharmacology. (1991) [Pubmed]
  25. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Kudo, S., Odomi, M. Eur. J. Clin. Pharmacol. (1998) [Pubmed]
  26. Potencies of haloperidol metabolites as inhibitors of the human noradrenaline, dopamine and serotonin transporters in transfected COS-7 cells. Bryan-Lluka, L.J., Siebert, G.A., Pond, S.M. Naunyn Schmiedebergs Arch. Pharmacol. (1999) [Pubmed]
  27. Haloperidol and reduced haloperidol concentrations and psychiatric ratings in schizophrenic patients treated with ascorbic acid. Straw, G.M., Bigelow, L.B., Kirch, D.G. Journal of clinical psychopharmacology. (1989) [Pubmed]
  28. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study. Chang, W.H., Lin, S.K., Jann, M.W. Journal of clinical psychopharmacology. (1991) [Pubmed]
  29. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Ulrich, S., Neuhof, S., Braun, V., Meyer, F.P. International clinical psychopharmacology. (1999) [Pubmed]
  30. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Jann, M.W., Chang, W.H., Lam, Y.W., Hwu, H.G., Lin, H.N., Chen, H., Chen, T.Y., Lin, S.K., Chien, C.P., Davis, C.M. Prog. Neuropsychopharmacol. Biol. Psychiatry (1992) [Pubmed]
WikiGenes - Universities